Editor's Desk: Kim Kardashian West's tempest in a bottle

Could Kardashian West's now-notorious Diclegis social post be more than an OPDP case study?

Editor's Desk: Off-label and on the record

Taking a look back at what's happened—and what hasn't happened—on the healthcare communications policy front so far this summer

Editor's Desk: Intrigues de Palais

Can agencies prove that regulations no longer hinder Grand Prix-level branded work?

Pharmanormal activities

When Monique Levy, one of the most-level-headed analysts in the pharma industry, calls attention to a mysterious phenomenon, you listen.

Editor's Desk: And the researchers go wild

Apple's ResearchKit could accelerate the pace at which industry approaches start-ups building products in the patient-facing part of health tech

Editor's Desk—Pill+: Now I'm a Believer

If you look at this as simply a tool to drive your brand, you've missed the point

Editor's Desk: Trials and innovations

How should pharma organize around adjacencies to therapeutics?

Editor's Desk: Whither the fast followers?

Will DIY and the mHealth movement be the catalysts driving change?

Disruption on display

As these 40 standouts show, the industry is ready to move forward

Adherence is in the behavior

There needs to be a greater effort put into the issue of adherence. What can academia, providers, pharma and payers do to address this pressing need?


Email Newsletters


Specialty medicines continue to be a hot category, one in which spending has surged behind products that treat medicine's most complex diseases. This eBook lays out the needs and hurdles along the specialty drug pathway, explaining how stakeholders are working to get meds into patients' hands and ease their experience. Click here to download.